Highest-materiality recent filing
Azenta completes sale of B Medical Systems for $63M; $35M vendor loan to buyer
Sale closed July 1, 2026; fixed purchase price $63M: $28M cash at closing, $35M via secured vendor loan.
Azenta Q2 revenue $145M, GAAP EPS -$3.41; cuts FY2026 guidance, extends long-range plan to 2029
Organic revenue declined 3% YoY; $149M non-cash goodwill impairment on Multiomics unit.
Azenta appoints Trey Martin as Multiomics President; Ginger Zhou steps down
Trey Martin appointed President of Multiomics effective April 6, 2026; reports to CEO John Marotta.
Thelema informed Azenta on March 27, 2026 that financing for the B Medical Systems acquisition has not been secured.
Azenta acquires UK Biocentre for GBP 20.5M to expand European biorepository footprint
Total consideration of GBP 20.5M net of cash, including up to GBP 1.8M contingent milestone payments.
Azenta Q1 revenue $149M flat; GAAP EPS -$0.11; non-GAAP EPS $0.09; reaffirms FY2026 guidance
Revenue $149M (+1% YoY); organic revenue -1%. Sample Mgmt $81M flat; Multiomics $67M (+1%).
Director Alan P. Malus resigns from Azenta Board effective Jan 29, 2026
Malus resigned due to full-time commitments at another company.
Azenta stockholders elect directors, approve equity plan amendment and say-on-pay
All 10 director nominees elected; Dipal Doshi received 32,984,474 votes for.
Azenta sells B Medical Systems to related-party Thelema for $63M; close by Mar 31, 2026
Sale of B Medical Systems subsidiary to Thelema S.À R.L. for USD 63M; Thelema is majority-owned by Azenta VP & B Medical CEO Luc Provost.
Azenta authorizes $250M share repurchase program through 2028
Board authorized repurchase of up to $250M of common stock, effective Dec 9, 2025 through Dec 31, 2028.
Azenta Q4 revenue $159M, +6% YoY; FY2026 guidance 3-5% organic growth, margin expansion 300 bps
Q4 revenue $159M, +6% YoY (organic +4%); FY revenue $594M, +4% (organic +3%).
Azenta Q3 revenue flat at $144M; non-GAAP EPS $0.19 vs $0.14 YoY; reaffirms FY2025 guidance
Revenue $144M flat YoY; organic revenue down 2%. Sample Management Solutions -4%, Multiomics +4%.
Azenta VP and Chief Accounting Officer Violetta Hughes resigns effective Aug 6, 2025
Violetta Hughes, VP and Chief Accounting Officer, voluntarily resigns effective August 6, 2025.
Azenta GC Jason Joseph departs; Ephraim Starr appointed as General Counsel
Jason W. Joseph to cease as SVP, General Counsel & Secretary on May 15, 2025; employment ends June 30, 2025.
Azenta Q2 revenue $143M up 5% YoY; reaffirms FY2025 guidance
Revenue $143M (+5% YoY, organic +6%); Sample Mgmt Solutions $80M (+8%), Multiomics $64M (+2%).
Azenta President of Sample Management Solutions David Wang departs; consultant role through Dec 9
President of Sample Management Solutions David Wang's employment ends April 9, 2025; consulting period runs through December 9, 2025.
Azenta Q1 FY25 revenue rises 4% YoY to $148M; adjusted EBITDA margin improves 400 bps to 9.0%
GAAP diluted EPS from continuing ops -$0.21 (vs -$0.13 YoY); total diluted EPS -$0.29 (vs -$0.28).
For FY2024 (12 months ended Sep 30, 2024), continuing ops revenue $573.2M, operating loss $50.6M.
Azenta reports Q4 FY2024 revenue $170M; plans to sell B Medical; appoints Lawrence Lin CFO
FY2024 combined Sample Mgmt & Multiomics organic revenue grew 4%; Q4 organic growth 5%.
Azenta appoints Cornog, Koffey, Malus to board; forms Value Creation Committee
Appoints William Cornog (ex-KKR Capstone), Alan Malus (ex-Thermo Fisher EVP), and activist Quentin Koffey (Politan, 9.4% owner) as independent directors.
Azenta appoints John Marotta as President and CEO; Schwartz retires after 14-year tenure
John Marotta becomes President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz.
Q3 revenue $173M, up 4% YoY, organic growth 5%. Sample Mgmt Solutions $81M (+7%), Multiomics $64M (flat), B Medical $29M (+7%).
Azenta CEO Stephen Schwartz retiring; board initiates search for successor
Dr. Schwartz retires as CEO and director effective May 7, 2024; will continue until successor appointed.
Azenta Q2 revenue $159M (+7%); non-GAAP EPS $0.05; $111M goodwill impairment; guides FY rev lower
Revenue $159M, up 7% YoY; organic growth 7%; B Medical revenue up 51% to $23M.
Azenta holds Investor Day on March 14; presentation attached but no details disclosed in filing
Investor Day held March 14, 2024, with presentation provided as Exhibit 99.1.
Azenta Q1 rev $154M (-13% YoY), GAAP EPS ($0.28), non-GAAP $0.02; reaffirms FY24 guide
Revenue $154M, down 13% YoY; organic revenue -15%; combined Sample Mgmt & Multiomics grew 2% organic.
Azenta shareholders elect all 9 directors, approve say-on-pay, ratify PwC at annual meeting
All nine director nominees elected with support ranging from 47.2M to 49.9M votes.
Azenta realigns into three segments and provides historical recast data
Effective Oct 1, 2023, Azenta restructured into Multiomics, Sample Management Solutions, and B Medical Systems.
Director Ellen M. Zane to leave Azenta board after 2024 annual meeting
Ellen M. Zane notified Azenta she will not stand for re-election at the Jan. 30, 2024 annual meeting.
Azenta Q4 rev $172M (+25%); guides FY24 5-8% organic growth; adds $500M buyback; board nominees
Q4 revenue $172M (+25% YoY, +2% organic); FY revenue $665M (+20%, -1% organic).
Azenta names Herman Cueto as CFO, succeeding retiring Lindon Robertson; reaffirms Q4 guidance
Herman Cueto appointed EVP & CFO effective Oct 16, 2023; previously SVP Finance at BD (NYSE: BDX).
Azenta Q3 revenue up 25% YoY to $166M; guides Q4 $155-173M
Revenue $166M, up 25% YoY; organic growth 2%; Life Sciences Products +57%, Services +7%.
Azenta Q2 FY23 revenue $148M, GAAP EPS loss $0.03, guided Q3 below consensus
Revenue $148M (+2% YoY; -17% sequentially); non-GAAP diluted EPS ($0.06) vs $0.12 a year ago.
Revenue $178M, up 28% YoY; organic growth ex-COVID of 7%.
All 10 director nominees elected; Frank Casal got 60.1M for, 277k withhold; Ellen Zane got 56.4M for, 4.0M withhold.
Acquisition of B Medical Systems closed Oct 3, 2022; amendment provides required financial statements.
Azenta enters $500M accelerated share repurchase; initial delivery of ~6.1M shares
Azenta entered $500M accelerated share repurchase with JPMorgan; $500M payment on Nov 28, 2022.
Q4 revenue $138M (flat YoY); organic growth ex-COVID 12%; GAAP EPS from cont. ops ($0.07); non-GAAP $0.16.
Azenta COO Matthew McManus departs effective October 14, 2022
Matthew McManus and Azenta agreed he would no longer serve as COO, effective October 14, 2022.
Azenta completes €424M acquisition of B Medical Systems for cold chain expansion
Paid ~€424M in cash for B Medical Systems, with up to €50M in contingent earn-out based on financial metrics.
Azenta to acquire B Medical Systems for €410M cash plus €50M earnout
Cash purchase price €410M; up to €50M additional contingent consideration based on performance milestones.
Azenta Q3 revenue $133M (+3% YoY); GAAP EPS -$0.09, non-GAAP $0.12
Revenue $133M (+3% YoY); organic growth 6% despite FX headwind; Services up 6%, Products down 3%.
Azenta preliminary Q3 FY2022 revenue $133M (+3%); GAAP EPS loss ($0.13)-($0.08)
Revenue ~$133M, +3% YoY (organic +6% after ~3pp currency drag).
Azenta buys Barkey for €80M; expands cell & gene therapy cold-chain products
Purchase price approx €80M (~$86M) for Barkey, a provider of controlled-rate thawing devices.
Azenta Q2 rev $146M (+12% YoY); Semi Automation sale closes, total diluted EPS $28.15
Revenue from continuing ops $146M, up 12% YoY; Life Sciences Services rev $92M (+19%), Products $54M (+2%).
Azenta Q1 revenue $140M (+18% YoY); completes $3B sale of semiconductor business to THL
GAAP diluted EPS from continuing ops $0.04; total diluted EPS $0.58 (incl. $0.54 from discontinued ops).
Azenta completes $3.0B sale of semiconductor automation business to Thomas H. Lee Partners
Net proceeds approximately $2.4B after taxes, fees, and working capital adjustments.
Azenta stockholders elect all director nominees, approve say-on-pay, ratify auditor.
All 10 director nominees elected; Frank E. Casa received 65,986,712 votes for, 220,524 withhold, 3,825,163 broker non-votes.
Corporate name changed from Brooks Automation, Inc. to Azenta, Inc. effective December 1, 2021.
Brooks Automation to rename Azenta, Inc., ticker AZTA from Dec 1
Name change to Azenta, Inc. effective Dec 1, 2021; ticker changes to AZTA on Nasdaq.
On May 15, 2025, the Company appointed Ephraim Starr as its Senior Vice President, General Counsel and Secretary to succeed Mr. Joseph.
On May 12, 2025, Azenta, Inc. (the “Company”) and Jason W. Joseph, Senior Vice President, General Counsel and Secretary, agreed that Mr. Joseph would cease to serve in that role, effective May 15, 2025 and that Mr. Joseph’s employment with the Company would cease effective June 30, 2025.
On April 7, 2025, Azenta, Inc. (the “Company”) and David Wang, President of Sample Management Solutions, agreed that Mr. Wang’s employment with the Company would cease effective April 9, 2025
Herman Cueto, who is departing from his role at the Company.
appointed Lawrence Lin as its Executive Vice President and Chief Financial Officer, effective as of Effective Time
Effective November 1, 2024, the Board appointed each of Mr. Cornog and Mr. Malus (together with Mr. Koffey, the “New Directors”) as a member of the Board, with an initial term expiring at the 2025 Annual Meeting.
Pursuant to the Cooperation Agreement, on November 1, 2024, the Board appointed Mr. Koffey as a member of the Board, effective November 1, 2024, with an initial term expiring at the 2025 Annual Meeting.
Effective November 1, 2024, the Board appointed each of Mr. Cornog and Mr. Malus (together with Mr. Koffey, the “New Directors”) as a member of the Board, with an initial term expiring at the 2025 Annual Meeting.
the Board also increased the size of the Board from eight to nine members and appointed Mr. Marotta as a member of the Board
succeed the Company’s current President and Chief Executive Officer, Dr. Stephen Schwartz, who as previously announced is retiring effective as of the Start Date
Dr. Schwartz resigned as a director of the Company effective as of May 7, 2024
Dr. Stephen Schwartz informed the Company of his intention to retire from his position as President and Chief Executive Officer and a director of the Company
Max materiality 0.90 · Median 0.70 · Most common event earnings